Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aim: The MOMENTUM 3 pivotal trial established superiority of the HeartMate 3 (HM3) left ventricular assist device (LVAD), a fully magnetically levitated centrifugal‐flow pump, over the HeartMate II axial‐flow pump. We now evaluate HM3 LVAD outcomes in a single‐arm prospective continuous access protocol (CAP) post‐pivotal trial study. Methods and results: We enrolled 2200 HM3 implanted patients (515 pivotal trial and 1685 CAP patients) and compared outcomes including survival free of disabling stroke or reoperation to replace or remove a malfunctioning device (primary composite endpoint), overall survival and major adverse events at 2 years. The 2‐year primary endpoint [76.7% vs. 74.8%; adjusted hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.71–1.08, P = 0.21] and overall survival (81.2% vs. 79.0%) were similar among CAP and pivotal cohorts despite sicker patients (more intra‐aortic balloon pump use and INTERMACS profile 1) in CAP who were more often intended for destination therapy. Survival was similar between the CAP and pivotal trial in transplant ineligible patients (79.1% vs. 76.7%; adjusted HR 0.89, 95% CI 0.68–1.16, P = 0.38). In a pooled analysis, the 2‐year primary endpoint was similar between INTERMACS profiles 1–2 (‘unstable’ advanced heart failure), profile 3 (‘stable’ on inotropic therapy), and profiles 4–7 (‘stable’ ambulatory advanced heart failure) (75.7% vs. 77.6% vs. 72.9%, respectively). The net burden of adverse events was lower in CAP (adjusted rate ratio 0.93, 95% CI 0.88–0.98, P = 0.006), with consequent decrease in hospitalization. Conclusions: The primary results of accumulating HM3 LVAD experience suggest a lower adverse event burden and similar survival compared to the pivotal MOMENTUM 3 trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report
Mehra, M. R., Uriel, N., Naka, Y., Cleveland, J. C., Yuzefpolskaya, M., Salerno, C. T., Walsh, M. N., Milano, C. A., Patel, C. B., Hutchins, S. W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900486 · Cited by 1,312
Self-citationChambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
Khush, K. K., Cherikh, W. S., Chambers, D. C., Harhay, M. O., Hayes, D., Hsich, E., Meiser, B., Potena, L., Robinson, A., Rossano, J. W., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.004 · Cited by 960
Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure
Rogers, J. G., Pagani, F. D., Tatooles, A. J., Bhat, G., Slaughter, M. S., Birks, E. J., Boyce, S. W., Najjar, S. S., Jeevanandam, V., Anderson, A. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602954 · Cited by 758 · cited 1×
“HM3 LVAD implanted patients, demonstrated survival outcomes that exceeded those observed in trials or registry experiences.(7,8)”
ResultA Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure
Mehra, M. R., Naka, Y., Uriel, N., Goldstein, D. J., Cleveland, J. C., Colombo, P. C., Walsh, M. N., Milano, C. A., Patel, C. B., Jorde, U. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1610426 · Cited by 751
Self-citationTwo-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
Mehra, M. R., Goldstein, D. J., Uriel, N., Cleveland, J. C., Yuzefpolskaya, M., Salerno, C., Walsh, M. N., Milano, C. A., Patel, C. B., Ewald, G. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800866 · Cited by 722
Self-citationThe Society of Thoracic Surgeons Intermacs 2020 Annual Report
Molina, E. J., Shah, P., Kiernan, M. S., Cornwell, W. K., Copeland, H., Takeda, K., Fernandez, F. G., Badhwar, V., Habib, R. H., Jacobs, J. P., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2020.12.038 · Cited by 587 · cited 1×
“HM3 LVAD implanted patients, demonstrated survival outcomes that exceeded those observed in trials or registry experiences.(7,8)”
ResultSelf-citationKormos, R. L., Cowger, J., Pagani, F. D., Teuteberg, J. J., Goldstein, D. J., Jacobs, J. P., Higgins, R. S., Stevenson, L. W., Stehlik, J., Atluri, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.11.013 · Cited by 451
Self-citationUriel, N. Y., Colombo, P. C., Cleveland, J. C., Long, J. W., Salerno, C. T., Goldstein, D. J., Patel, C. B., Ewald, G. A., Tatooles, A. J., Silvestry, S., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028303 · Cited by 295
Self-citationFully Magnetically Levitated Left Ventricular Assist System for Treating Advanced HF
Netuka, I., Sood, P., Pya, Y., Zimpfer, D., Krabatsch, T., Garbade, J., Rao, V. A., Morshuis, M., Marasco, S. F., Beyersdorf, F., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.083 · Cited by 260 · cited 1×
“pointed to reduced pump thrombosis and increased pump durability.(5,6) The pivotal MOMENTUM 3 trial, which included 515 .”
BackgroundBourque, K., Cotter, C., Dague, C., Harjes, D. I., Dur, O., Duhamel, J., Spink, K., Walsh, K., & Burke, E. (2016) · ASAIO Journal · doi:10.1097/mat.0000000000000388 · Cited by 237 · cited 2×
“The HM3 LVADs were speci cally designed to reduce haemocompatibility-related adverse events including pump thrombosis, strokes and bleeding.(11) The pivotal trial phase of MOMENTUM 3 con rmed superiority of the HM3 pump in these domains but non-haemocompatibility-related adverse events were largely unaltered.”
BackgroundMethodNetuka, I., Ivák, P., Tučanová, Z., Gregor, S., Szárszoi, O., Sood, P., Crandall, D., Rimsans, J., Connors, J. M., & Mehra, M. R. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.03.002 · Cited by 168 · cited 1×
“Trials to evaluate reduced exposure to anticoagulation regimens or to avoid the use of aspirin are ongoing in an effort to further control bleeding events.(28,29) Efforts to fully internalize the LVAD system and reduce driveline infections are being actively pursued.”
BackgroundSelf-citationGoldstein, D. J., Naka, Y., Horstmanshof, D., Ravichandran, A. K., Schroder, J., Ransom, J., Itoh, A., Uriel, N., Cleveland, J. C., Raval, N. Y., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.5323 · Cited by 165 · cited 2×
“The advent of the HM3 pump has led to greater con dence in LVAD use among transplant ineligible patients such that even regulatory authorities in the United States have abandoned the use of such terminology in preference for a single indication of use in patients refractory to pharmacological disease-modifying therapy…”
BackgroundSelf-citationHeatley, G. J., Sood, P., Goldstein, D. J., Uriel, N. Y., Cleveland, J. C., Middlebrook, D., & Mehra, M. R. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.021 · Cited by 158
Self-citationLeft Ventricular Assist Devices for Lifelong Support
Pinney, S., Anyanwu, A., Lala, A., Teuteberg, J. J., Uriel, N. Y., & Mehra, M. R. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.031 · Cited by 123 · cited 1×
“Prior studies enforced such a dichotomy and reduced con dence in outcomes with those deemed transplant ineligible due to observations of lower survival in such patient cohorts.(16,17) The advent of the HM3 pump has led to greater con dence in LVAD use among transplant ineligible patients such that even regulatory auth…”
BackgroundSelf-citationSchmitto, J. D., Pya, Y., Zimpfer, D., Krabatsch, T., Garbade, J., Rao, V. A., Morshuis, M., Beyersdorf, F., Marasco, S. F., Sood, P., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1284 · Cited by 109
Zimpfer, D., Gustafsson, F., Potapov, E. V., Pya, Y., Schmitto, J. D., Berchtold‐Herz, M., Morshuis, M., Shaw, S. M., Saeed, D., Ii Jacob Lavee, I., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehaa639 · Cited by 77 · cited 1×
“entry criteria were less well controlled and endpoints relied on site-reported, non-adjudicated outcomes.(9) Once the randomized”
MethodHealthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study
Mehra, M. R., Salerno, C. T., Cleveland, J. C., Pinney, S., yuzefpolskaya, M., Milano, C. A., Itoh, A., Goldstein, D. J., Uriel, N. Y., Gulati, S., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035722 · Cited by 75
Self-citationSidhu, K., Lam, P. H., & Mehra, M. R. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.013 · Cited by 56 · cited 2×
“patients refractory to medical therapy, with evidence of markedly improved survival and quality of life.(1) The Multicenter Study of”
BackgroundSelf-citationContinuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach
Jorde, U. P., Shah, A. M., Sims, D. B., Madan, S., Siddiqi, N., Luke, A., Saeed, O., Patel, S. R., Murthy, S., Shin, J. J., et al. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.01.063 · Cited by 15 · cited 1×
“These observations endorse the importance of effective patient and care provider education as well as multidisciplinary ambulatory care.(22) We observed an increased early RVAD requirement in the post-pivotal trial cohort despite similar rates of right heart failure over time.”
BackgroundSelf-citationGustafsson, F. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.019 · Cited by 5 · cited 1×
“Trials to evaluate reduced exposure to anticoagulation regimens or to avoid the use of aspirin are ongoing in an effort to further control bleeding events.(28,29) Efforts to fully internalize the LVAD system and reduce driveline infections are being actively pursued.”
Background
Cited by
Peled, Y., Ducharme, A., Kittleson, M., Bansal, N., Stehlik, J., Amdani, S., Saeed, D., Cheng, R., Clarke, B., Dobbels, F., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.05.010 · Cited by 240
Metadata
- Authors
- Mehra, M. R., Cleveland, J. C., Uriel, N., Cowger, J. A., Hall, S., Horstmanshof, D., Naka, Y., Salerno, C. T., Chuang, J., Williams, C., Goldstein, D. J., & on behalf of the MOMENTUM 3 Investigators
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-05-18
- Volume
- 23
- Issue
- 8
- Pages
- 1392-1400
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W3159511774
- Cited by
- 183
- References
- 21
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.